Search results for the GEO ID: GSE33658 |
(Click on the check boxes provided under "Select for analysis", to initiate grouping) |
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down) |
|
GSM ID | GPL ID |
Select for analysis |
Title |
Source name |
Description |
Characteristics |
GSM832390 | GPL570 |
|
breast, pre AF treatment (H7_1349)
|
Human breast, pre AF treatment
|
type_of_rx: AF
pre_or_post_treatment: pre
response: PD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 76
baseline tumor size (cm): 7x8
patient id (to identify the 2 chips from the same patient): 13491389
|
RE1_H7_1349_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832390
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Jun 07 2012
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832390/suppl/GSM832390.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832391 | GPL570 |
|
breast, post AF treatment (H8_1389)
|
Human breast, post AF treatment
|
type_of_rx: AF
pre_or_post_treatment: post
response: PD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 76
baseline tumor size (cm): 7x8
patient id (to identify the 2 chips from the same patient): 13491389
|
RE1_H8_1389_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832391
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832391/suppl/GSM832391.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832392 | GPL570 |
|
breast, pre AF treatment (H15_1682)
|
Human breast, pre AF treatment
|
type_of_rx: AF
pre_or_post_treatment: pre
response: PR
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 72
baseline tumor size (cm): 6x5
patient id (to identify the 2 chips from the same patient): 16821717
|
RE1_H15_1682_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832392
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832392/suppl/GSM832392.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832393 | GPL570 |
|
breast, post AF treatment (H16_1717)
|
Human breast, post AF treatment
|
type_of_rx: AF
pre_or_post_treatment: post
response: PR
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 72
baseline tumor size (cm): 6x5
patient id (to identify the 2 chips from the same patient): 16821717
|
RE1_H16_1717_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832393
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832393/suppl/GSM832393.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832394 | GPL570 |
|
breast, pre AF treatment (H1_1278)
|
Human breast, pre AF treatment
|
type_of_rx: AF
pre_or_post_treatment: pre
response: SD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 68
baseline tumor size (cm): 8x8
patient id (to identify the 2 chips from the same patient): 12781328
|
RE1_H1_1278_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832394
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832394/suppl/GSM832394.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832395 | GPL570 |
|
breast, post AF treatment (H4_1328)
|
Human breast, post AF treatment
|
type_of_rx: AF
pre_or_post_treatment: post
response: SD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 68
baseline tumor size (cm): 8x8
patient id (to identify the 2 chips from the same patient): 12781328
|
RE1_H4_1328_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832395
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832395/suppl/GSM832395.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832396 | GPL570 |
|
breast, pre AF treatment (H12_1628)
|
Human breast, pre AF treatment
|
type_of_rx: AF
pre_or_post_treatment: pre
response: SD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 56
baseline tumor size (cm): 8x7
patient id (to identify the 2 chips from the same patient): 16281659
|
RE1_H12_1628_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832396
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832396/suppl/GSM832396.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832397 | GPL570 |
|
breast, post AF treatment (H14_1659)
|
Human breast, post AF treatment
|
type_of_rx: AF
pre_or_post_treatment: post
response: SD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 56
baseline tumor size (cm): 8x7
patient id (to identify the 2 chips from the same patient): 16281659
|
RE1_H14_1659_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832397
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832397/suppl/GSM832397.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832398 | GPL570 |
|
breast, pre AF treatment (H23_2233)
|
Human breast, pre AF treatment
|
type_of_rx: AF
pre_or_post_treatment: pre
response: SD
er_status: pos
pgr_status_: neg
her_2_status: neg
baseline age (years): 50
baseline tumor size (cm): missing
patient id (to identify the 2 chips from the same patient): 22332259
|
RE1_H23_2233_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832398
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832398/suppl/GSM832398.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832399 | GPL570 |
|
breast, post AF treatment (H24_2259)
|
Human breast, post AF treatment
|
type_of_rx: AF
pre_or_post_treatment: post
response: SD
er_status: pos
pgr_status_: neg
her_2_status: neg
baseline age (years): 50
baseline tumor size (cm): missing
patient id (to identify the 2 chips from the same patient): 22332259
|
RE1_H24_2259_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832399
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832399/suppl/GSM832399.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832400 | GPL570 |
|
breast, pre AFI treatment (H3_1296)
|
Human breast, pre AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: pre
response: CR
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 72
baseline tumor size (cm): 3x3
patient id (to identify the 2 chips from the same patient): 12961346
|
RE1_H3_1296_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832400
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832400/suppl/GSM832400.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832401 | GPL570 |
|
breast, post AFI treatment (H6_1346)
|
Human breast, post AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: post
response: CR
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 72
baseline tumor size (cm): 3x3
patient id (to identify the 2 chips from the same patient): 12961346
|
RE1_H6_1346_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832401
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832401/suppl/GSM832401.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832402 | GPL570 |
|
breast, pre AFI treatment (H11_1610)
|
Human breast, pre AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: pre
response: CR
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 59
baseline tumor size (cm): 3x3
patient id (to identify the 2 chips from the same patient): 16101647
|
RE1_H11_1610_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832402
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832402/suppl/GSM832402.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832403 | GPL570 |
|
breast, post AFI treatment (H13_1647)
|
Human breast, post AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: post
response: CR
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 59
baseline tumor size (cm): 3x3
patient id (to identify the 2 chips from the same patient): 16101647
|
RE1_H13_1647_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832403
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832403/suppl/GSM832403.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832404 | GPL570 |
|
breast, pre AFI treatment (H9_1575)
|
Human breast, pre AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: pre
response: PD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 73
baseline tumor size (cm): 7x6
patient id (to identify the 2 chips from the same patient): 15751594
|
RE1_H9_1575_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832404
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832404/suppl/GSM832404.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832405 | GPL570 |
|
breast, post AFI treatment (H10_1594)
|
Human breast, post AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: post
response: PD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 73
baseline tumor size (cm): 7x6
patient id (to identify the 2 chips from the same patient): 15751594
|
RE1_H10_1594_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832405
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832405/suppl/GSM832405.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832406 | GPL570 |
|
breast, pre AFI treatment (H2_1279)
|
Human breast, pre AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: pre
response: PR
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 67
baseline tumor size (cm): 9x7
patient id (to identify the 2 chips from the same patient): 12791332
|
RE1_H2_1279_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832406
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832406/suppl/GSM832406.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832407 | GPL570 |
|
breast, post AFI treatment (H5_1332)
|
Human breast, post AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: post
response: PR
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 67
baseline tumor size (cm): 9x7
patient id (to identify the 2 chips from the same patient): 12791332
|
RE1_H5_1332_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832407
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832407/suppl/GSM832407.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832408 | GPL570 |
|
breast, pre AFI treatment (H18_1930)
|
Human breast, pre AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: pre
response: PR
er_status: pos
pgr_status_: neg
her_2_status: neg
baseline age (years): 87
baseline tumor size (cm): 5x3
patient id (to identify the 2 chips from the same patient): 19301950
|
RE1_H18_1930_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832408
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832408/suppl/GSM832408.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832409 | GPL570 |
|
breast, post AFI treatment (H20_1950)
|
Human breast, post AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: post
response: PR
er_status: pos
pgr_status_: neg
her_2_status: neg
baseline age (years): 87
baseline tumor size (cm): 5x3
patient id (to identify the 2 chips from the same patient): 19301950
|
RE1_H20_1950_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832409
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832409/suppl/GSM832409.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832410 | GPL570 |
|
breast, pre AFI treatment (H17_1910)
|
Human breast, pre AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: pre
response: SD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 57
baseline tumor size (cm): 5x5
patient id (to identify the 2 chips from the same patient): 19101935
|
RE1_H17_1910_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832410
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832410/suppl/GSM832410.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
GSM832411 | GPL570 |
|
breast, post AFI treatment (H19_1935)
|
Human breast, post AFI treatment
|
type_of_rx: AFG
pre_or_post_treatment: post
response: SD
er_status: pos
pgr_status_: pos
her_2_status: neg
baseline age (years): 57
baseline tumor size (cm): 5x5
patient id (to identify the 2 chips from the same patient): 19101935
|
RE1_H19_1935_U133Plus2.0.CEL
Gene expression data from human breast cancer
|
Sample_geo_accession | GSM832411
| Sample_status | Public on Dec 20 2011
| Sample_submission_date | Nov 14 2011
| Sample_last_update_date | Dec 20 2011
| Sample_type | RNA
| Sample_channel_count | 1
| Sample_organism_ch1 | Homo sapiens
| Sample_taxid_ch1 | 9606
| Sample_treatment_protocol_ch1 | After a baseline tumor biopsy, patients were randomized to receive Anastrazole/fulvestrant(AF) or anastrazole/Fulvestrant/Gefitinib (AFG) for 3 weeks, then a second biopsy was obtained. After that all patients received the AFG treatment.
| Sample_growth_protocol_ch1 | N/A
| Sample_molecule_ch1 | total RNA
| Sample_extract_protocol_ch1 | Trizol extraction
| Sample_label_ch1 | biotin
| Sample_label_protocol_ch1 | 3' IVT express
| Sample_hyb_protocol | Standard Affymetix protocol for 3' IVT design
| Sample_scan_protocol | Scanner GCS3000 7G
| Sample_data_processing | Expression were estimated using BRB Array Tools software, GCRMA method
| Sample_platform_id | GPL570
| Sample_contact_name | Anna,,Tsimelzon
| Sample_contact_institute | Baylor College of Medicine
| Sample_contact_address | 1 Baylor Plaza
| Sample_contact_city | Houston
| Sample_contact_state | Texas
| Sample_contact_zip/postal_code | 77096
| Sample_contact_country | USA
| Sample_supplementary_file | ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM832nnn/GSM832411/suppl/GSM832411.CEL.gz
| Sample_series_id | GSE33658
| Sample_data_row_count | 54675
| |
|
|
|
Make groups for comparisons |
(2 groups will be compared at a time) |
|
Select GSMs and click on "Add groups" |
Enter the group name here: |
|
|
|